'We're going to miss the next Keytruda': Lilly, Merck, Gilead and PhRMA CEOs talk IRA consequences
Almost 10 years ago, Merck ushered superstar cancer drug Keytruda across the FDA finish line for the first time, opening the door to dozens of additional indications over the years. It was a “once-in-a-lifetime, lighting-in-a-bottle” discovery that wouldn …